HKEX: 1541
2026 Interim Report
Earlier from Immuneonco Biopharmaceuticals (shanghai) Inc Class H
- Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
- Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China